COVID-19 Patients Displayed MERS-CoV Cross-Reactivity
Researchers found that severe COVID-19 cases generated antibodies capable of binding to MERS-CoV spike proteins.
Updated on Oct. 13, 2026 in Diseases — General
Live Poll
Do you trust that new medical testing methods are generally making healthcare more accurate?
A study conducted in the Netherlands revealed that individuals with severe COVID-19 infections produced antibodies that cross-react with MERS-CoV. This immune response primarily targeted conserved S2 epitopes on the virus spike.
Why it matters
Understanding this cross-reactivity is essential for refining diagnostic tests, as severe infections can trigger responses to conserved viral regions that might cause false positives in other coronavirus screenings.
Severe COVID-19 patients showed a median MERS-CoV S2 binding level of 67.0 IU/mL, while commercial MERS-CoV S1 ELISA results remained below the positivity threshold. Among the cohort, 11 patients exhibited neutralizing antibody titers ranging from 26 to 694.
The players
EUROIMMUN
This is a diagnostic laboratory entity that serves as a commercial MERS-CoV S1 ELISA provider.
The details
The study utilized serum samples from persons in the Netherlands to test for MERS-CoV cross-reactivity using an in-house ELISA with full spike protein and S1 and S2 subunits. While S1 binding did not correlate with neutralization, severe COVID-19 patients showed distinct binding to the S2 subunit and full spike proteins.
Timeline
The research findings were published on October 13, 2026.
The Big Picture
This study follows a pattern set by previous research into coronavirus cross-reactivity established by the 2003 SARS response protocols. By identifying how severe COVID-19 alters antibody specificity, the findings suggest that diagnostic specificity must be carefully tuned to account for conserved viral regions.
These findings alert the healthcare community to the potential for diagnostic interference in coronavirus testing following severe illness. Patients who have recently recovered from severe COVID-19 should be aware that their immune response may influence results in specialized MERS-CoV testing.
The takeaway
Severe viral infections can lead to broad antibody responses that may complicate diagnostic accuracy across related virus families. Clinicians should verify whether a patient has a history of severe COVID-19 when interpreting results from non-specific coronavirus diagnostic assays.
Further reading
For more information on similar studies, visit the Diseases — General section.
More information
For technical information on standard testing protocols, visit the commercial MERS-CoV S1 ELISA provider.
Source note: This article includes information reported by Cdc.
Live Poll
Do you trust that new medical testing methods are generally making healthcare more accurate?
